is a topic covered in the Davis's Drug Guide
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Quiring, Courtney, et al. "Reslizumab." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110405/all/reslizumab.
Quiring C, Sanoski CA, Vallerand AH. Reslizumab. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110405/all/reslizumab. Accessed October 16, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Reslizumab. In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110405/all/reslizumab
Quiring C, Sanoski CA, Vallerand AH. Reslizumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 October 16]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110405/all/reslizumab.
TY - ELEC
T1 - reslizumab
ID - 110405
A1 - Quiring,Courtney,
AU - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110405/all/reslizumab
PB - F.A. Davis Company
ET - 16
DB - Pediatrics Central
DP - Unbound Medicine